

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

Rituximab Unspecified Plan of Treatment for GPA/MPA

PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:
Patient Name:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG
Gender:	Allergies:
	<input type="checkbox"/> See list <input type="checkbox"/> NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

M31.30 - Granulomatosis with Polyangiitis (GPA/Wegener's Granulomatosis)
M31.7 - Microscopic Polyangiitis (MPA)
- Other:

REQUESTED DOCUMENTATION:

1	Insurance information	IF NO:	IF YES:
2	Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3	Most recent labs including CBC with diff	REQUIRED WASHOUT	NEXT INFUSION DATE:
4	Full medication list / Tried and failed therapies	FROM PREVIOUS	
5	REQUIRED: HBsAg, anti-HBc, and anti-HBs	THERAPY:	
			IF ORDER CHANGE:
			Continue current order until insurance approved

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive rituximab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, newly diagnosed cardiac arrhythmias, severe abdominal pain or vomiting, and/or surgery.

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

*Per FDA labeling, Acetaminophen PO, Diphenhydramine IVP, and Methylprednisolone IVP is suggested prior to infusion

IV	Diphenhydramine	25mg	50mg		PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
					Cetirizine	10mg				
					Loratadine	10mg				
					Other:					

SPECIFIC MEDICATION:

<input type="checkbox"/>	Rituxan	Any rituximab biosimilar may be used according to payer guidelines
<input type="checkbox"/>	Ruxience	
<input type="checkbox"/>	Truxima	
<input type="checkbox"/>	Riabni	

MAINTENANCE DOSE: (begin ___ months after last induction dose)

<input type="checkbox"/>	500mg/500ml NS IV to infuse per step protocol
<input type="checkbox"/>	1000mg/500ml NS IV to infuse per step protocol
<input type="checkbox"/>	Other: _____

INDUCTION DOSE:

<input type="checkbox"/>	375mg/m ² per 250 - 500ml NS IV to infuse per step protocol once weekly x 4 weeks
<input type="checkbox"/>	Other: _____

MAINTENANCE FREQUENCY:

<input type="checkbox"/>	Infuse dose every <input type="checkbox"/> 4 months <input type="checkbox"/> 6 months
<input type="checkbox"/>	Other: _____

SPECIAL/LAB ORDERS:

<input type="checkbox"/>	_____
<input type="checkbox"/>	_____

<input checked="" type="checkbox"/>	Refills x 12 months unless noted otherwise here:
-------------------------------------	--

Prescriber to monitor patient for symptoms of HBV infection and reactivation as clinically appropriate.

LINE USE/CARE ORDERS:

<input checked="" type="checkbox"/>	Start PIV/Access CVC
<input checked="" type="checkbox"/>	Flush device per facility standard flushing procedure
<input checked="" type="checkbox"/>	Provide nursing care per Palmetto Infusion Nursing Procedures and post observation if indicated.

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures)

DATE

Dispense as written/Brand medically necessary	Substitution permitted